KRAS and malignant colon neoplasm: Supporting these observations, KRAS-mutant lung, pancreatic and colon cancer showed significantly higher expression of NOP56 than KRAS-WT tumors (Fig. 1C) and patients with KRAS-mutant lung adenocarcinoma, pancreatic and colon cancer characterized by a higher NOP56 level are associated with significantly shorter survival (Fig. 1D).